CDKN2A and glioblastoma: The Arf promoter monitors latent oncogenic signals in vivo (Zindy et al. 2003), and accordingly, Arf-null mice are highly prone to spontaneous tumor development, especially glioblastomas, carcinomas, and fibrosarcomas (Kamijo et al. 1999).